JP2008534472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534472A5 JP2008534472A5 JP2008502385A JP2008502385A JP2008534472A5 JP 2008534472 A5 JP2008534472 A5 JP 2008534472A5 JP 2008502385 A JP2008502385 A JP 2008502385A JP 2008502385 A JP2008502385 A JP 2008502385A JP 2008534472 A5 JP2008534472 A5 JP 2008534472A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- pyrimidin
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 17
- -1 1,2-dihydro-indenyl Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- BWIHJLOBZMKPKS-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyrimidine Chemical class N1C=CC(C=2N=CC=CN=2)=N1 BWIHJLOBZMKPKS-UHFFFAOYSA-N 0.000 claims 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 102000004257 Potassium Channel Human genes 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 108020001213 potassium channel Proteins 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010034759 Petit mal epilepsy Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 208000028311 absence seizure Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- NOIAFRXJAOIRIO-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-6-methyl-n-(4-methylphenyl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=CC(C)=CC=2)=N1 NOIAFRXJAOIRIO-UHFFFAOYSA-N 0.000 claims 1
- GCYURZUJNGSNKB-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-6-methyl-n-naphthalen-2-ylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=C3C=CC=CC3=CC=2)=N1 GCYURZUJNGSNKB-UHFFFAOYSA-N 0.000 claims 1
- KCZNYEKQVDFBBF-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-6-methyl-n-phenylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=CC=CC=2)=N1 KCZNYEKQVDFBBF-UHFFFAOYSA-N 0.000 claims 1
- DGBGJAANMYAVCJ-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n,n-diethyl-6-methylpyrimidin-4-amine Chemical compound CCN(CC)C1=CC(C)=NC(N2C(=CC(C)=N2)C)=N1 DGBGJAANMYAVCJ-UHFFFAOYSA-N 0.000 claims 1
- PXQJUGVKEYTNBD-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n-(4-methylphenyl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC=2C=CC(C)=CC=2)=N1 PXQJUGVKEYTNBD-UHFFFAOYSA-N 0.000 claims 1
- KTCGBPVALCAPDU-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC=2C=C(C=CC=2)C(F)(F)F)=N1 KTCGBPVALCAPDU-UHFFFAOYSA-N 0.000 claims 1
- FCTRCVYLPZXYLH-UHFFFAOYSA-N 5-bromo-n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Br)C(NC=2C=CC(Cl)=CC=2)=N1 FCTRCVYLPZXYLH-UHFFFAOYSA-N 0.000 claims 1
- XYUUDWDCHUFTKW-UHFFFAOYSA-N 5-bromo-n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Br)C(NC2CCCCC2)=N1 XYUUDWDCHUFTKW-UHFFFAOYSA-N 0.000 claims 1
- ASQXYGAONBBSHT-UHFFFAOYSA-N 5-chloro-n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Cl)C(NC=2C=CC(Cl)=CC=2)=N1 ASQXYGAONBBSHT-UHFFFAOYSA-N 0.000 claims 1
- TZLDAYRGEQCNRS-UHFFFAOYSA-N 5-chloro-n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Cl)C(NC2CCCCC2)=N1 TZLDAYRGEQCNRS-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- TTXQIWXVTCZSTO-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=C(Cl)C(Cl)=CC=2)=N1 TTXQIWXVTCZSTO-UHFFFAOYSA-N 0.000 claims 1
- HEKSTMZFTPWLRQ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-5-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(C)C(NC=2C=CC(Cl)=CC=2)=N1 HEKSTMZFTPWLRQ-UHFFFAOYSA-N 0.000 claims 1
- MYCRDMLFNQGDBT-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC=2C=CC(Cl)=CC=2)=N1 MYCRDMLFNQGDBT-UHFFFAOYSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- BTRUVNBLFGQQHU-UHFFFAOYSA-N n-benzyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NCC=2C=CC=CC=2)=N1 BTRUVNBLFGQQHU-UHFFFAOYSA-N 0.000 claims 1
- XITVRRQKYRJRMA-UHFFFAOYSA-N n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC2CCCCC2)=N1 XITVRRQKYRJRMA-UHFFFAOYSA-N 0.000 claims 1
- SBBUCGYZZUIBIB-UHFFFAOYSA-N n-cyclopentyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC2CCCC2)=N1 SBBUCGYZZUIBIB-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical group ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500415 | 2005-03-22 | ||
| US66615405P | 2005-03-29 | 2005-03-29 | |
| PCT/EP2006/060857 WO2006100212A1 (en) | 2005-03-22 | 2006-03-20 | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534472A JP2008534472A (ja) | 2008-08-28 |
| JP2008534472A5 true JP2008534472A5 (enExample) | 2009-05-07 |
Family
ID=36390135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502385A Abandoned JP2008534472A (ja) | 2005-03-22 | 2006-03-20 | カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1863796A1 (enExample) |
| JP (1) | JP2008534472A (enExample) |
| WO (1) | WO2006100212A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| EP1966184B1 (en) | 2005-12-20 | 2010-08-25 | NeuroSearch A/S | Pyridinyl-quinazoline derivatives and their medical use |
| AU2007304195A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| US20100105705A1 (en) | 2007-03-28 | 2010-04-29 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
| EP2142547A1 (en) | 2007-03-28 | 2010-01-13 | NeuroSearch A/S | Purinyl derivatives and their use as potassium channel modulators |
| US20100179203A1 (en) * | 2007-07-04 | 2010-07-15 | Antonio Nardi | Novel pyrazole derivatives useful as potassium channel modulators |
| EP2251001A4 (en) | 2008-02-08 | 2013-01-09 | Shiseido Co Ltd | SKIN BLEACHING AND EXTERNAL PREPARATION FOR THE SKIN |
| CN102177154A (zh) * | 2008-09-02 | 2011-09-07 | 神经研究公司 | 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用 |
| US8268838B2 (en) | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
| EP2344501A1 (en) | 2008-09-26 | 2011-07-20 | NeuroSearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| DK2414365T3 (da) | 2009-04-01 | 2014-03-31 | Aniona Aps | SUBSTITUEREDE [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINER OG ANVENDELSE HERAF SOM KALIUMKANALMODULATORER |
| US20120095025A1 (en) | 2009-04-01 | 2012-04-19 | Neurosearch A/S | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS |
| US8685987B2 (en) | 2009-04-01 | 2014-04-01 | Ataxion, Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators |
| EP2527341B1 (en) * | 2010-01-18 | 2014-06-18 | Shiseido Co., Ltd. | Process for preparation of pyrimidinylpyrazole compounds |
| WO2013104577A1 (en) | 2012-01-11 | 2013-07-18 | Acesion Pharma Aps | Benzimidazolyl-acetamide derivatives useful as potassium channel modulators |
| CA2976937C (en) * | 2015-02-17 | 2023-04-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| DK3258938T3 (da) | 2015-02-17 | 2021-02-01 | Univ Arizona State | Phenothiazinanaloger som mitokondrie terapeutiske midler |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
| BR112019014814B1 (pt) * | 2017-01-23 | 2024-03-12 | Novartis Ag | Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio |
| AU2019366312B2 (en) | 2018-10-22 | 2025-04-24 | Novartis Ag | Crystalline forms of potassium channel modulators |
| US12312333B2 (en) * | 2021-09-30 | 2025-05-27 | Chapman University | SK channel positive allosteric modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54117029A (en) * | 1978-02-28 | 1979-09-11 | Hokko Chem Ind Co Ltd | Agricultural and horticultural microbicide |
| JPS6059883B2 (ja) * | 1978-05-08 | 1985-12-27 | 北興化学工業株式会社 | 農園芸用殺菌剤 |
| US6458823B1 (en) * | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
| EP1361879A1 (en) * | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| AU2003212634A1 (en) * | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| TW200418835A (en) * | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| KR20060032190A (ko) * | 2003-07-02 | 2006-04-14 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널의 조절제로서 유용한 피리미딘 |
-
2006
- 2006-03-20 JP JP2008502385A patent/JP2008534472A/ja not_active Abandoned
- 2006-03-20 EP EP06725151A patent/EP1863796A1/en not_active Withdrawn
- 2006-03-20 WO PCT/EP2006/060857 patent/WO2006100212A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519995A5 (enExample) | ||
| US11197867B2 (en) | Aminopyrimidinyl compounds | |
| US10717711B2 (en) | Amino quinazolines as kinase inhibitors | |
| AU2010339423C1 (en) | Therapeutic compounds and related methods of use | |
| JP2008533087A5 (enExample) | ||
| US7622486B2 (en) | Pyridine compounds, process for their preparation and compositions containing them | |
| AU2019283921A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| JP2009532375A5 (enExample) | ||
| JP2010502674A5 (enExample) | ||
| CN103917525A (zh) | Lrrk2激酶活性的抑制剂 | |
| JP2009519979A5 (enExample) | ||
| CA2473510A1 (en) | Pyrimidine derivatives as rho-kinase inhibitors | |
| JP2010522718A5 (enExample) | ||
| JP2008520665A5 (enExample) | ||
| CA2900308A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| JP2020506895A (ja) | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 | |
| JP2010524896A5 (enExample) | ||
| KR20120005499A (ko) | 퀴나졸린디온 유도체의 심혈관 분야에서의 치료 용도 | |
| US10202401B2 (en) | Process for making tetracyclic heterocycle compounds | |
| CN112939948B (zh) | 新型含喹唑啉类化合物及其中间体与应用 | |
| US9428492B2 (en) | Secondary alcohol substituted triazoles as PDE10 inhibitors | |
| US8273880B2 (en) | Pyrazole compounds with inhibitory activity against ROS kinase | |
| US20160039812A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| JP7465266B2 (ja) | 細菌感染症の治療と予防のための三環式化合物 | |
| JP2010509249A5 (enExample) |